A Randomized, Placebo-Controlled Trial Evaluating Safety and Immunogenicity of the Killed, Bivalent, Whole-Cell Oral Cholera Vaccine in Ethiopia

Sachin N. Desai,† Zenebe Akalu,‡ Samuel Teshome, Mekonnen Teferi, Lawrence Yamuah, Deok Ryun Kim, Jae Seung Yang, Jemal Hussein, Ju Yeong Park, Mi Seong Jang, Chalachew Mesganaw, Hawult Taye, Demissew Beyene, Ahmed Bedru, Ajit Pal Singh, Thomas F. Wierzba, and Abraham Aseffa

International Vaccine Institute, Seoul, Korea; Armawer Hansen Research Institute, Addis Ababa, Ethiopia

Abstract. Killed whole-cell oral cholera vaccine (OCV) has been a key component of a comprehensive package including water and sanitation measures for recent cholera epidemics. The vaccine, given in a two-dose regimen, has been evaluated in a large number of human volunteers in India, Vietnam, and Bangladesh, where it has demonstrated safety, immunogenicity, and clinical efficacy. We conducted a double-blind randomized placebo-controlled trial in Ethiopia, where we evaluated the safety and immunogenicity of the vaccine in 216 healthy adults and children. OCV was found to be safe and elicited a robust immunological response against Vibrio cholerae O1, with 81% adults and 77% children demonstrating seroconversion 14 days after the second dose of vaccine. This is the first study to evaluate safety and immunogenicity of the vaccine in a population outside Asia using a placebo-controlled, double-blind, randomized study design.

BACKGROUND

Cholera remains a serious global challenge with disease burden estimated at over 3 million cases and more than 100,000 deaths throughout much of the developing world.1 Many large and prolonged outbreaks have resulted in cholera becoming endemic not only in many parts of Africa, but also in Haiti, where cholera had not been previously reported for nearly a century.2 In recent years, the World Health Assembly has called for the incorporation of oral cholera vaccines (OCVs) as part of an integrated, comprehensive strategy of cholera prevention and control.3 Currently, two killed OCVs are prequalified by the World Health Organization (WHO). Both Dukoral (Crucell, Leiden, The Netherlands), a whole-cell vaccine supplemented with recombinant cholera toxin B subunit (WC-rBS), and Shanchol (Shantha Biotechnics Ltd., Hyderabad, India), a bivalent whole-cell vaccine without cholera toxin (WC), have demonstrated immunogenicity4–6 and efficacy7,8 in preventing cholera in endemic settings. Because Shanchol is less expensive and does not require the coadministration of buffer, it can be delivered in a faster and less cumbersome manner. This has been corroborated during recent preventive and reactive campaigns in Bangladesh, India, Haiti, South Sudan, and Guinea.9,10

In Ethiopia, “acute watery diarrhea” (AWD) and cholera have been used interchangeably, largely due to limited diagnostic capacity. Since 1993, yearly AWD outbreaks, encompassing various infectious etiologies including laboratory-confirmed cholera, have affected numerous regions throughout sub-Saharan Africa.11 Severe diarrhea caused by Vibrio cholerae O1 has been an important cause of morbidity and mortality in Ethiopia, with the Federal Ministry of Health reporting over 22,000 cases and 219 deaths (case fatality rate 1%) in 2006.12 AWD due to V. cholerae O1 has been reported in five regions, with the most populous region (Oromia) reporting cholera in five out of six years during the 2006–2011 period.13 Cholera outbreaks in developing countries occur in both endemic and epidemic settings. Populations with endemic cholera presumably have high levels of preexisting immunity following age-related acquisition patterns because of recurrent cholera exposures. Conversely, outbreaks in less endemic settings tend to occur in populations with limited preexisting immunity. This helps to explain why younger children with less background immunity have made up a higher proportion of cases in endemic settings, while cholera incidence tends to be age independent in epidemic settings. The killed bivalent formulation of OCV has been evaluated in a large number of human volunteers in Vietnam, India, and Bangladesh, where its safety, immunogenicity,5,6,16 and clinical protective efficacy have been demonstrated.8 During a recent OCV campaign in rural Haiti, investigators assessed immune response in a region without recent historical exposure to V. cholerae and found the two-dose OCV regimen to be highly immunogenic in Haitian adults and children.17 In this placebo-controlled, double-blind randomized trial, we evaluated the safety and immunogenicity of killed bivalent whole-cell OCV in a high-risk population residing in a less endemic region outside Asia.

METHODS

Participants. The study was conducted at the Clinical Trials Center of the Armauer Hansen Research Institute (AHRI) in an urban community near Addis Ababa, Ethiopia. Healthy adults (18 years and above) and children (aged 1–17 years) were recruited. Main exclusion criteria considered were pregnancy (as determined by urine pregnancy test for females aged 12 years and above), ongoing illness, immune-compromising conditions, diarrhea (defined as having three or more loose/watery stools within a 24-hour period during the past 6 weeks) and gastrointestinal symptoms (abdominal pain, loss of appetite, nausea, and vomiting) in the past 24 hours, or previous receipt of OCV. Written informed consent was obtained by study physicians for all adults and parents/guardians of participating children, as well as written assent for 12- to 17-year-old-participants.

Regulatory and ethics approvals. The trial protocol was approved by the Institutional Review Board of the International Vaccine Institute (IVI) in Seoul, Korea, the AHRI/All Africa Leprosy, Tuberculosis and Rehabilitation Training Center (ALERT) Ethics Review Committee (AAERC),
the National Health Research Ethics Review Committee (NHRERC), and the Food, Medicine, and Healthcare Administration and Control Authority of Ethiopia (FMHACA) in Addis Ababa. The study was monitored by an independent local study monitor and external clinical monitors from IVI and Shantha Biotechnics Ltd (Hyderabad, India). Furthermore, an impartial Data and Safety Monitoring Board reviewed all the safety data from the trial. The trial was registered in ClinicalTrials.gov (NCT01524640).

Study design. This is an individually randomized, double-blind, placebo-controlled trial among healthy adults (aged 18 years and above) and children (aged 1–17 years) randomized into two groups at 1:1 ratio to receive two oral doses of either killed bivalent (O1 and O139) whole-cell OCV or a nonbiological placebo. Assuming a 5% diarrheal rate among placebo and vaccine recipients alike, to exclude a vaccine–placebo difference in the rate of diarrhea of greater than 20% (upper bound of the one-tailed 95% confidence intervals [CI]) with a power of 0.8, a minimum of 33 participants would be required in each intervention group. For serum vibriocidal responses, assuming a background rate of 5% seroconversion among placebo recipients after the second dose and a true rate of vibriocidal response in the vaccine group of 60% to exclude a vaccine–placebo difference of 30% with a power of 0.8, a minimum of 43 participants would be necessary for each group. Using the Farrington and Manning method of precision-based sample size calculation18 and adjusting for a 20% attrition rate, we calculated the need for 54 participants each in the vaccine and placebo groups, requiring a total of 108 adults and 108 children.

Randomization and blinding. Four lists of individualized numbers were computer generated by a statistician from IVI, who was not involved in the study, to achieve stratified randomization by age group: 1–5, 6–10, 11–17, and ≥18 years. Randomization was performed in variable blocks of 4–8, to ensure that both balance between intervention groups and blinding are maintained. Study agents were pre-labeled by Shantha Biotechnics personnel, who were not involved in the conduct or monitoring of the trial. The IVI, local safety monitor, and the manufacturer-held sealed copies of the randomization list, which was not opened until all data for analysis had been frozen and a hard copy had been given to the local monitor. All study personnel and participants were blinded to treatment assignment during the duration of the study.

Intervention and administration. Each dose of vaccine contained heat and formalin-killed whole-cell bacteria consisting of five strains of V. cholerae O1 and O139. The placebo consisted of a sugar-buffer solution, similar in appearance to the vaccine. Participants were randomized to receive two doses of vaccine or placebo at a 14-day interval and instructed not to eat 1 hour before and 30 minutes after dosing. After proper shaking and inspection of the vial by the study physician, a member of the field team administered the 1.5-mL dose of study agent, followed by offering the participant a small cup of water. All participants were observed for 30 minutes following dosing and were interviewed by research staff for three consecutive days after each dose to monitor for adverse events. Active surveillance via questioning at ensuing study visits was conducted for any adverse or serious adverse events for 28 days following the dosing regimen. All participants were instructed to contact study staff or visit the clinical trial study physician if any adverse events presented during the study period. Venous blood samples were obtained immediately before dosing on day 0, before dosing on day 14, and on day 28 (2 weeks following second dose). Serum samples were stored at −20°C and shipped to IVI, where vibriocidal antibody assays were performed.

Outcomes. We investigated whether the killed bivalent OCV was safe and immunogenic among adults and children residing in a less endemic area in Ethiopia. The primary endpoint for safety was the proportion of participants experiencing adverse events 3 days after dosing or severe adverse events within 14 days following either dose. For immunogenicity, the primary endpoint was to measure the proportion of participants demonstrating seroconversion, defined as a 4-fold or greater rise in titers of serum vibriocidal antibodies relative to baseline and 14 days after the second dose.

Statistical and laboratory methods. Statistical analysis. Data were entered in Visual FoxPro 9.0 (Microsoft Corp., Redmond, WA) and analyses were performed in SAS 9.3 (SAS Institute, Cary, NC). Analyses for comparisons of dichotomous outcomes such as seroconversion were performed with the χ² test or Fisher’s exact test when an expected cell count was less than five. For comparisons of vibriocidal titers, Student’s t test was performed using pooled method or Satterthwaite method depending on whether the variances were equal or not. Vibriocidal titers and fold increases were logarithmically transformed before statistical analyses. Nonparametric Wilcoxon rank-sum test and Kolmogorov–Smirnov test were performed depending on equality of variance if data were not normally distributed. Multiple linear regression models were fitted to assess vaccine effect after controlling confounding variable. In the model, the logarithms of vibriocidal titers at 2 weeks following the second dose was the dependent variable, and the vaccine status (vaccine or placebo), logarithm of the baseline vibriocidal titers, and confounding variable were fitted as the independent variables. The primary outcomes that were proportion of participants with adverse events within 3 days following dosing and vibriocidal seroconversion were evaluated with one-tailed 97.5% CI using the Wilson Score method.19 Statistical evaluations of all other comparisons were two tailed.

Laboratory analysis. Venipuncture was performed before the first dose, 14 days after dose 1, and 14 days after dose 2 for all the 216 study participants enrolled in the study. At each study visit, 3 mL blood was collected from all participants. Serum was separated and stored in a dedicated freezer at −20°C in the microbiology laboratory at AHRI (Addis Ababa) and then shipped to IVI (Seoul) for analysis. The serum vibriocidal antibody titers were determined using the microtiter technique as previously described.20 An increase of titer by 4-fold or greater between baseline and postimmunization sera was considered to meet the criteria for seroconversion, which was a primary end point for the study. Vibriocidal titers were measured against O1 Inaba, O1 Ogawa, and O139.

RESULTS

Enrollment. Enrollment and follow-up of all participants are shown in Figure 1. A total of 216 participants (108 adults, 108 children) were recruited from December 2012 to July 2013.
Of the 216 participants, 106/108 adults and 106/108 children received both doses of the assigned study agent and provided all three blood samples. Characteristics of study participants are shown in Table 1. Age and weight were comparable between adult and child participants receiving either study agent. We had a significantly higher number of adult males receiving vaccine (59% versus 41%, \( P = 0.03 \)), for which vaccine effect was adjusted using a multiple regression model.

**Safety.** All participants were included in the safety analysis. No significant differences in rates of adverse events were observed between the vaccine and placebo groups (Table 2). No adverse events were reported in any vaccine recipients within 3 days of dosing. Only one child who received vaccine reported of mild fever and sore throat within 14 days of dosing (day 12) and resolved following medication. No serious adverse events were reported during the trial.

**Immunogenicity: vibriocidal antibody titers.** A per protocol analysis was conducted for immunogenicity data, including 212 participants who completed all study visits. Table 3 illustrates baseline geometric mean titers (GMT), geometric mean fold rise (GMFr), and seroconversion rates as defined by a ≥4-fold rise in titers from baseline GMT to 14 days following the first and second doses. Among vaccine recipients, the baseline GMT to *V. cholerae* O1 Inaba was 3.5, 8.3, and 16.9 for 1- to 5-year-, 6- to 17-year, and ≥18-year age groups, respectively. GMFr of *V. cholerae* O1 Inaba vibriocidal antibody titers among vaccine recipients were 4.3 (1–5 years), 32.6 (6–17 years), and 15.1 (≥18 years) and demonstrated statistically significant differences compared with the placebo arms in both adults and children. Seroconversion rates against *V. cholerae* O1 Inaba was 89% in older children (6–17 years) and 81% in adults (≥18 years). Although

| Characteristics | Vaccine (N = 54) | Placebo (N = 54) | \( P \) value | Vaccine (N = 54) | Placebo (N = 54) | \( P \) value |
|-----------------|-----------------|-----------------|-------------|-----------------|-----------------|-------------|
| Gender          | Male (%)        | Female (%)      |             | Male (%)        | Female (%)      |             |
|                 | 32 (59.3)       | 22 (40.7)       | 0.03        | 21 (38.9)       | 33 (61.1)       | –           |
| Age (years)     | Mean (SD)       | 35.33 (8.35)    | 35.58 (9.72) | 0.89           | 9.09 (4.58)     | 8.79 (4.52) | 0.73        |
|                 | Median          | 33.25           | 33.92       | 0.94           | 8.57            | 7.68        | 0.64        |
| Weight (kg)     | Mean (SD)       | 62.35 (12.95)   | 59.72 (11.79) | 0.27           | 25.83 (12.30)   | 25.93 (13.13) | 0.97        |
|                 | Median          | 63.00           | 59.50       | 0.22           | 21.50           | 20.50       | 0.88        |

\( SD = \) standard deviation.
children aged 1–17 years demonstrated a 77% seroconversion rate, responses were markedly lower (53%) in the youngest age group (1–5 years) (Table 4). Because of significant difference in enrollment of vaccinated male and female adults (P = 0.03, Table 1), a multiple regression model was used to adjust for sex. The crude and adjusted estimates of GMT were similar and remained statistically significant (P < 0.001, Table 3) after correction for the higher number of vaccinated adult males. Baseline GMTs were low in both adults (16.9) and children (6.0), with significantly higher GMT and seroconversion rates in the vaccine group. Overall, 23% adults and 18% children had baseline GMTs over 160. AEs = adverse events; SAEs = serious adverse events.

### Table 2

| Adults | Vaccine | Placebo | P value |
|--------|---------|---------|---------|
| Number of AEs within 3 days after first vaccine dose | 0 | 1* | – |
| Number of AEs within 3 days after second vaccine dose | 0 | 0 | – |
| Number (%) of participants with ≥ 1 AEs 3 days following dosing regimen | 0/54 (0) | 1/54 (1.9) | – |
| Number (%) of participants with SAEs 28 days following dosing regimen | 0 | 0 | – |
| Children | Vaccine | Placebo | P value |
| Number of AEs within 3 days after first vaccine dose | 0 | 0 | – |
| Number of AEs within 3 days after second vaccine dose | 0 | 0 | – |
| Number (%) of participants with ≥ 1 AEs 3 days following dosing regimen | 0/54 (0) | 0/54 (0) | – |
| Number (%) of participants with SAEs 28 days following dosing regimen | 0/54 (0) | 0/54 (0) | – |

*Geometric mean fold rise (GMFr) from baseline to 14 days after first dose or from baseline to 14 days after second dose. Adjusted GMFr values after first or second dose to correct for difference in male:female enrolled adult vaccine and placebo recipients all remained statistically significant when compared with placebo (P < 0.001); O1 Inaba (11.8 and 14.5, respectively), O1 Ogawa (8.2 and 7.6, respectively), and O139 (2.9 and 3.2, respectively).

### Table 3

| Adults (aged 18 years and above) | O1 Inaba | O1 Ogawa | O139 |
|----------------------------------|----------|----------|------|
| Vaccine group (N = 54) | Placebo group (N = 54) | P value | Vaccine group (N = 46) | Placebo group (N = 49) | P value | Vaccine group (N = 50) | Placebo group (N = 53) | P value |
| Baseline GMT | 16.1 | 16.1 | 1 | 23.7 | 43.1 | 0.26 | 4.8 | 4.1 | 0.71 |
| 14 days GMT | 188.1 | 17.1 | < 0.001 | 318.1 | 59.2 | < 0.001 | 14.6 | 4.3 | 0.01 |
| after first GMF* rise | 11.2 | 1.1 | < 0.001 | 13.4 | 1.4 | < 0.001 | 3.1 | 1.1 | < 0.001 |
| vaccine dose | 37 (70) | 2 (4) | < 0.001 | 24 (65) | 5 (11) | < 0.001 | 13 (28) | 2 (4) | 0.000 |
| 14 days GMT | 254.1 | 18.8 | < 0.001 | 306.4 | 61 | < 0.001 | 15.1 | 4.2 | < 0.001 |
| after second GMF* rise | 15.1 | 1.2 | < 0.001 | 12.9 | 1.4 | < 0.001 | 3.2 | 1 | < 0.001 |
| No. seroconverted† (%) | 43 (81) | 4 (7) | < 0.001 | 26 (70) | 6 (13) | < 0.001 | 14 (30) | 2 (4) | 0.001 |

| Children (aged 1–17 years) | O1 Inaba | O1 Ogawa | O139 |
|----------------------------|----------|----------|------|
| Vaccine group (N = 54) | Placebo group (N = 54) | P value | Vaccine group (N = 45) | Placebo group (N = 48) | P value | Vaccine group (N = 49) | Placebo group (N = 53) | P value |
| Baseline GMT | 6.2 | 8.5 | 0.48 | 4.2 | 7.2 | 0.17 | 1.6 | 1.6 | 0.92 |
| 14 days GMT | 136.8 | 10.8 | < 0.001 | 143.6 | 7.5 | < 0.001 | 17.1 | 1.6 | < 0.001 |
| after first GMF* rise | 21.9 | 1.3 | < 0.001 | 34.6 | 1.1 | < 0.001 | 10.7 | 1.0 | < 0.001 |
| vaccine dose | 39 (74) | 4 (7) | < 0.001 | 36 (80) | 4 (7) | < 0.001 | 26 (53) | 1 (2) | < 0.001 |
| 14 days GMT | 106.7 | 12.4 | < 0.001 | 143.6 | 7 | < 0.001 | 9.6 | 1.8 | < 0.001 |
| after second GMF* rise | 17.1 | 1.5 | < 0.001 | 34.6 | 1 | < 0.001 | 6 | 1.1 | < 0.001 |
| vaccine dose | 41 (77) | 6 (11) | < 0.001 | 38 (84) | 3 (5) | < 0.001 | 21 (43) | 3 (6) | < 0.001 |

*GMF = geometric mean fold rise. O1 Inaba, O1 Ogawa, and O139 were statistically significant in the vaccinated group compared with placebo recipients in all age groups, the values were much less pronounced compared with V. cholerae O1 Inaba and O1 Ogawa (Tables 3 and 4).

**DISCUSSION**

Adding to the recent work by Charles and others,17 these results support the claim that the killed bivalent OCV, Shanchol, can elicit a strong immune response in areas that are less endemic to V. cholerae. This bridging study is the first to evaluate safety and immunogenicity of this vaccine in adults and children aged 1–17 years.
a population outside Asia using a placebo-controlled, double-blind, randomized study design. Vibriocidal antibody response remains the most studied immunologic marker of cholera infection, with 40–80% individuals living in endemic areas having detectable antibodies by 15 years of age.²² Though this vaccine was found to be immunogenic in adults and children, the youngest age group demonstrated a lower response of vibriocidal antibody titers and proportion of populations in Kolkata (4.5), India, and Bangladesh (9).⁶ which was substantially increased when compared with similar elevated levels of GMFr in serum antibodies in adults (26.8), in this study is probably due to limited exposure to V. cholerae. Hence, in less endemic regions, such as our study area, all ages respond as an immunologically naïve cohort. Understandably, this data differ from regions with continual exposure to cholera, such as India and Bangladesh, because of the amount of background natural cholera exposure. Still, a limitation of this trial is that it cannot be directly compared with other immunogenicity trials because of differences in study protocol and absence of standardization of vibriocidal titers across laboratories.

Intriguingly, the immunogenicity results of this OCV in Haitian vaccines revealed vibriocidal titers similar to age-matched cohorts from Bangladesh following a two-dose OCV regimen. Differences between the Haiti trial and the current Ethiopia trial may be explained by the fact that participants in Haiti may have developed background immunity since vibriocidal titers were measured in the middle of 2013, with the epidemic starting October 2010. This may represent an immunologically primed population by boosting underlying immunity. In endemic settings, children have been shown to be able to mount vibriocidal and toxin-specific antibody, as well as memory B cell responses comparable to that of adults.²⁴ However, a diminished T cell response, as well as other important host factors in young children such as helminth coinfection, enteropathy, and micronutrient deficiencies²⁵ can serve as contributing factors to explain lower observed immune responses in this age group. An important similarity between the Haitian and Ethiopian study cohorts was how the vaccine was less immunogenic after the first vaccine dose, which suggests that there may be important differences in the response and that a two-dose regimen may be important in a non-historically endemic population.

A strong rise in GMFr as well as high seroconversion rates were noted in this study against both Inaba and Ogawa O1 strains. The vaccine is a bivalent formulation containing O1 and O139 strains. Though O139 emerged in the Bay of Bengal in 1992, it has been confined to southeast Asia. A robust response against O1 is of particular interest as it comprises the major cause of major outbreaks. However, while type-specific immunity is induced by infection, cross protective immunity between the two serotypes is incomplete.²⁶

Prolonged and frequent outbreaks, increased antibiotic resistance, and raised awareness of the role of climate change in disease burden have returned cholera as a focal discussion point by the international public health community. Though improved water quality, sanitation, and hygiene measures remain the foundation of cholera prevention efforts, major improvements to infrastructure continue to be a goal far out of reach for many of those affected. Public immunization campaigns with the modified, killed, whole-cell OCV have successfully been carried out in high-risk areas across Asia, Africa, and Hispaniola.⁹,¹¹,²⁷,²⁸ Though most trials have been conducted in Asia, this trial demonstrates that this vaccine can produce a robust immune response in less endemic populations. These trials can help pave the way for the

---

**TABLE 4**

| Children (aged 1–5 years) | Vaccine group | Placebo group | **P** value |
|--------------------------|---------------|---------------|------------|
|                          | **GMFr rise** |               |            |
| Baseline GMT             | 3.5           | 5             | 0.63       |
| 14 days GMT              | 25.5          | 5.8           | 0.06       |
| after first vaccine dose  |               |               |            |
| No. seroconverted (%)    | 11 (65)       | 1 (6)         | < 0.001    |
| 14 days GMT              | 15            | 7.4           | 0.38       |
| after second vaccine dose|               |               |            |
| No. seroconverted (%)    | 9 (53)        | 2 (11)        | 0.008      |

| Children (aged 6–17 years) | Vaccine group | Placebo group | **P** value |
|----------------------------|---------------|---------------|------------|
|                          | **GMFr rise** |               |            |
| Baseline GMT             | 8.3           | 11            | 0.58       |
| 14 days GMT              | 302           | 14.7          | < 0.001    |
| after first vaccine dose  |               |               |            |
| No. seroconverted (%)    | 28 (78)       | 3 (8)         | < 0.001    |
| 14 days GMT              | 269.1         | 16.2          | < 0.001    |
| after second vaccine dose|               |               |            |
| No. seroconverted (%)    | 32 (89)       | 4 (11)        | < 0.001    |

GMFr = geometric mean titers.

*Geometric mean fold rise from baseline GMT to V. cholerae (include O1 Inaba, O1 Ogawa, and O139) in children.

†Number with ≥ 4-fold rise in titers from baseline to 14 days after first dose or from baseline to 14 days after second dose.

‡P = 0.05 post hoc Bonferroni corrected.
possible use of this vaccine in any endemic region or outbreak setting throughout resource-scarce areas. Use of a cholera vaccine stockpile following disasters may offer an attractive mechanism for OCV introduction, with the hopes of yielding both public health and humanitarian benefits. As with any programmatic strategy, an effective surveillance program is paramount to assess the burden and impact of any potential outbreak. With proper disease detection programs in place, this evidence along with epidemiologic data could further support the potential use of this vaccine as part of a reactive strategy in an epidemic situation. A comprehensive cholera response that links prevention with care will require a concerted international effort to reach those who are most affected and in greatest need.

Received October 28, 2014. Accepted for publication March 22, 2015. Published online June 15, 2015.

Acknowledgments: We are grateful to all the participants who participated in this trial and our field staff. We thank Tesfamariam Mebratu, who served as the clinical trial team leader. We also thank to Samuel Ayale and Wondu Wagaye, who provided valuable support for this project.

Financial support: This work was supported by funding from LG Electronics. Armauer Hansen Research Institute (AHRl) is supported by core grants from Norwegian Agency for Development Cooperation (NORAD), Swedish International Development Cooperation Agency (SIDA), and received grants from European and Developing Countries Clinical Trials Partnership (EDCTP) and other consortium collaborative projects to strengthen its clinical trial team.

Disclaimer: The funding agency of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all of the data in the study and had final responsibility for the decision to submit for publication.

Authors’ addresses: Sachin N. Desai, Samuel Teshome, Deok Ryun Kim, Jae Seung Yang, Ju Yeong Park, Mi Seon Jang, Ajit Pal Singh, and Thomas F. Wierzba, Development and Delivery Unit, International Vaccine Institute, Seoul, Korea, E-mails: sdesai@ivi.int, steshome@ivi.int, drkim@ivi.int, jsyang@ivi.int, jjang@ivi.int, apalsinght@ivi.int, and twierzba@ivi.int. Zenebe Akalu, Mekonnen Teferi, Lawrence Yamuah, Jemal Hussein, Chalachew Mesganaw, Hawult Taye, Demissew Beyene, Ahmed Bedru, and Abraham Assefa, Clinical Trials Unit, Armauer Hansen Research Institute, Addis Ababa, Ethiopia, E-mails: zenebeakalu@yahoo.com, mekonneteferi@yahoo.com, yamauahji@yahoo.co.uk, jemalder@gmail.com, bestchale@yahoo.com, hawultachew@gmail.com, beyene88@hotmail.com, and aasseffa@gmail.com.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REFERENCES

1. Ali M, Lopez A, You Y, Kim Y, Sah B, Maskery B, Clemens J, 2012. The global burden of cholera. Bull World Health Organ 90: 209–218.

2. Harris JB, LaRocque RC, Charles RC, Mazumder RN, Khan AI, Bardhan PK, 2010. Cholera’s western front. Lancet 376: 1961–1965.

3. World Health Assembly, 2011. Cholera: Mechanism for Control and Prevention. Agenda Item 13.9 of the 64th World Health Assembly WHA64.15, July 2, 2014. Available at: http://www.who.int/cholera/technical/resolution/en/.

4. Clemens JD, Stanton BF, Chakraborty J, Sack DA, Khan MR, Huda S, Ahmed F, Harris JR, Yunus M, Khan MU, Svennerholm A-M, Jertborn M, Holmgren J, 1987. Subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reagogenicity and immunogenicity. J Infect Dis 155: 79–85.

5. Mahalanabis D, Lopez AL, Sur D, Deen J, Manna B, Kanungo S, von Seidlein L, Carbis R, Han SH, Shin SH, Attridge S, Rao R, Holmgren J, Clemens J, Bhattacharya SK, 2008. A randomized, placebo-controlled trial of the bivalent killed whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS One 3: e2323.

6. Saha A, Chowdhury ML, Khaham F, Bhuiyan MS, Chowdhury F, Khan AI, Khan IA, Clemens J, Ali M, Cravioto A, Qadri F. 2011. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladesh adults and children as young as 1 year of age. Vaccine 29: 8285–8292.

7. Clemens JD, Sack DA, Harris JR, Chakraborty J, Khan MR, Stanton BE, Kay BA, Khan MU, Yunus MD, Atkinson W, Svennerholm A-M, Holmgren J, 1986. Field trial of oral cholera vaccines in Bangladesh. Lancet 2: 124–127.

8. Bhattacharyya SK, Sur D, Ali M, Kanungo S, You YA, Manna B, Sah B, Niyogi SK, Park JK, Sarkar B, Puri MK, Kim DR, Deen JL, Holmgren J, Carbis R, Dingra MS, Donner A, Nair GB, Lopez AL, Wierzba TF, Clemens JD, 2013. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 13: 1050–1056.

9. Khan IA, Saha A, Chowdhury F, Khan AI, Uddin MJ, Begum YA, Riaz BK, Islam S, Ali M, Luby SP, Clemens JD, Cravioto A, Qadri F. 2013. Coverage and cost of a large oral cholera vaccination program in a high-risk cholera endemic urban population in Dhaka, Bangladesh. Vaccine 31: 6058–6064.

10. Kar SK, Sah B, Patnaik B, Kim YH, Kerketta AS, Shin S, Rath SB, Ali M, Mogasale V, Khuntia HK, Bhattachan A, You YA, Puri MK, Lopez AL, Maskery B, Nair GB, Clemens JD, Wierzba TF, 2014. Mass vaccination with a new, less expensive oral cholera vaccine using public health infrastructure in India: the Odisha model. PLoS Negl Trop Dis 8: e2629.

11. Ivers LC, Teng JE, Lascher J, Raymond M, Weigel J, Victor N, Jerome JG, Hilaire JI, Almazor CP, Ternier R, Cadet J, Francois J, Guillaume FD, Farmer PE, 2013. Use of oral cholera vaccine in Haiti: a rural demonstration project. Am J Trop Med Hyg 89: 617–624.

12. Luytren J, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M, Diallo AA, Itama C, Page A-L, Quilici M-L, Mengel MA, Eiros JM, Serafini M, Legros D, Grais RF, 2014. Use of Vibrio cholerae vaccine in an outbreak in Guinea. N Engl J Med 370: 2111–2120.

13. Mintz ED, Tauxe RV, 2013. Cholera in Africa: a closer look and a time for action. J Infect Dis 208 (Suppl 1): S167.

14. Federal Democratic Republican Of Ethiopia, Ministry of Health, 2011. Acute Watery Diarrhoea Prevention and Control Strategy. Addis Ababa, Ethiopia: Ministry of Health.

15. Bartels SA, Greenough PG, Tamir M, VanRooijen MJ, 2010. Investigation of a cholera outbreak in Ethiopia’s Oromiya region. Disaster Med Public Health Prep 4: 312–317.

16. Anh DD, Canh DG, Lopez AL, Thiem VG, Long PT, Son NH, Deen J, von Seidlein L, Carbis R, Han SH, Shin SH, Attridge S, Holmgren J, Clemens J, 2007. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine 25: 1149–1155.

17. Charles RC, Hilaire JI, Mayo-Smith LM, Teng JE, Jerome JG, Franke MF, Saha A, Yu Y, Kov A, Calderwood SB, Ryan ET, LaRocque RC, Almazor CP, Qadri F, Ivers LC, Harris JB, 2014. Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine. Shanchol, in Haiti. PLoS Negl Trop Dis 8: e2828.

18. Farrington CP, Manning G, 1990. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med 9: 1447–1454.

19. Newcombe RG, 1998. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 17: 857–872.

20. Yang JS, Kim HJ, Yun CH, Kang SS, Im J, Kim HS, Han SH, 2007. A semi-automated vibriocidal assay for improved
measurement of cholera vaccine-induced immune responses. 

J Microbiol Methods 71: 141–146.

21. Glass RI, Svennerholm A-M, Khan MR, Huda S, Imdadul Huq M, Holmgren J, 1985. Serorepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis 151: 236–242.

22. Harris JB, LaRocque RC, Chowdhury F, Khan AI, Logvinenko T, Faruque ASG, Ryan ET, Qadri F, Calderwood SB, 2008. Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh. PLoS Negl Trop Dis 2: e221.

23. Saha D, LaRocque RC, Khan AI, Harris JB, Begum YA, Akramuzzaman SM, Faruque ET, Ryan ET, Qadri F, Calderwood SB, 2004. Incomplete correlation of serum vibriocidal antibody titer with protection from Vibrio cholerae infection in urban Bangladesh. J Infect Dis 189: 2318–2322.

24. Leung DT, Chowdhury F, Calderwood SB, Qadri F, Ryan ET, 2012. Immune responses to cholera in children. Expert Rev Anti Infect Ther 10: 435–444.

25. Levine MM, 2010. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol 8: 129–138.

26. Longini IMJr., Yunus M, Zaman K, Siddique AK, Sack RB, Nizam A, 2002. Epidemic and endemic cholera trends over a 33-year period in Bangladesh. J Infect Dis 186: 246–251.

27. International Vaccine Institute, 2011. Cholera: Orissa Mass Vaccination Campaign, February 1, 2013. Available at: http://www .ivi.int/web/www/02_05_02.

28. Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M, Dialo AA, Itama C, Serafini M, Legros D, Grais RF, 2012. First outbreak response using an oral cholera vaccine in Africa: vaccine coverage, acceptability and surveillance of adverse events, Guinea. PLoS Negl Trop Dis 7: e2465.

29. Waldor MK, Hotez PJ, Clemens JD, 2010. A national cholera vaccine stockpile—a new humanitarian and diplomatic resource. N Engl J Med 363: 2279–2282.